Big Punches Come in Nanosizes for Chemoprevention

Literature to support the chemopreventive potential of several bioactive molecules has been prolific and convincing, but the clinical development of these agents has been slow. Major hurdles for development of bioactive chemoprevention approaches include low potency, lack of reliable formulations with high bioavailability that are suitable for oral administration, and relevant preclinical primary prevention models that use meaningful doses that can be translated to humans. The paper presented in this issue (Grandhi and colleagues) is an important step forward in this direction. It shows the efficacy of an oral, low dose, solid-lipid nanoparticles encapsulated curcumin and aspirin combined with free sulforaphane for long-term chemoprevention of pancreatic cancer in a carcinogen-induced hamster model. Reproducing this benefit in multiple cancer models, accompanied by development of intermediate markers of response will allow rapid translation of these findings. It will constitute the first successful multipronged attack at key pathways known to initiate and promote carcinogenesis. Cancer Prev Res; 6(10); 1007–10. ©2013 AACR.

[1]  S. Sukumar,et al.  Intraductal administration of a polymeric nanoparticle formulation of curcumin (NanoCurc) significantly attenuates incidence of mammary tumors in a rodent chemical carcinogenesis model: Implications for breast cancer chemoprevention in at-risk populations. , 2012, Carcinogenesis.

[2]  B. Rigas,et al.  Nanodelivery strategies in cancer chemotherapy: biological rationale and pharmaceutical perspectives. , 2012, Nanomedicine.

[3]  Ying Huang,et al.  Chemoprevention of Colon Cancer in a Rat Carcinogenesis Model Using a Novel Nanotechnology-Based Combined Treatment System , 2011, Cancer Prevention Research.

[4]  Jeffrey R. Wang,et al.  A Novel Combinatorial Nanotechnology-Based Oral Chemopreventive Regimen Demonstrates Significant Suppression of Pancreatic Cancer Neoplastic Lesions , 2013, Cancer Prevention Research.

[5]  R. Parhi,et al.  Preparation and characterization of solid lipid nanoparticles-a review. , 2012, Current drug discovery technologies.

[6]  Shivendra V. Singh,et al.  Cancer chemoprevention with dietary isothiocyanates mature for clinical translational research. , 2012, Carcinogenesis.

[7]  S. Mousa,et al.  Introducing nanochemoprevention as a novel approach for cancer control: proof of principle with green tea polyphenol epigallocatechin-3-gallate. , 2009, Cancer research.

[8]  S. Tacconelli,et al.  Mode of action of aspirin as a chemopreventive agent. , 2013, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[9]  S. Tacconelli,et al.  Mechanisms of the antitumoural effects of aspirin in the gastrointestinal tract. , 2012, Best practice & research. Clinical gastroenterology.

[10]  S. Safe,et al.  Inhibition of NFκB and Pancreatic Cancer Cell and Tumor Growth by Curcumin Is Dependent on Specificity Protein Down-regulation* , 2010, The Journal of Biological Chemistry.

[11]  D. Steinhilber,et al.  Phytochemicals resveratrol and sulforaphane as potential agents for enhancing the anti-tumor activities of conventional cancer therapies. , 2012, Current pharmaceutical biotechnology.

[12]  J. Cuzick,et al.  Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  E. Ho,et al.  Multi-targeted prevention of cancer by sulforaphane. , 2008, Cancer letters.

[14]  T. Kensler,et al.  Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Zhiwei Wang,et al.  Retracted: Notch‐1 down‐regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells , 2006, Cancer.

[16]  Paul Talalay,et al.  Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast. , 2007, Carcinogenesis.

[17]  Abhishek Sahu,et al.  Synthesis of novel biodegradable and self-assembling methoxy poly(ethylene glycol)-palmitate nanocarrier for curcumin delivery to cancer cells. , 2008, Acta biomaterialia.

[18]  S. Hecht,et al.  Phenethyl isothiocyanate and sulforaphane and their N-acetylcysteine conjugates inhibit malignant progression of lung adenomas induced by tobacco carcinogens in A/J mice. , 2005, Cancer research.

[19]  B. Aggarwal,et al.  Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. , 2008, Biochemical pharmacology.

[20]  B. Aggarwal,et al.  Curcumin: the Indian solid gold. , 2007, Advances in experimental medicine and biology.

[21]  V. Steele,et al.  Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. , 2000, The Journal of nutrition.

[22]  S. Jee,et al.  Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. , 2001, Anticancer research.

[23]  L. Bergmann,et al.  Curcumin Inhibits Constitutive STAT3 Phosphorylation in Human Pancreatic Cancer Cell lines and Downregulation of Survivin/BIRC5 Gene Expression , 2009, Cancer investigation.

[24]  Shadan Ali,et al.  Fluorocurcumins as Cyclooxygenase-2 Inhibitor: Molecular Docking, Pharmacokinetics and Tissue Distribution in Mice , 2009, Pharmaceutical Research.

[25]  S. Batra,et al.  Activation of ATM/Chk1 by curcumin causes cell cycle arrest and apoptosis in human pancreatic cancer cells , 2009, British Journal of Cancer.

[26]  F. Ahmad,et al.  Solid lipid nanoparticles of anticancer drug andrographolide: formulation, in vitro and in vivo studies , 2014, Drug development and industrial pharmacy.

[27]  A. Dennison,et al.  Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration , 2004, British Journal of Cancer.

[28]  T. Kensler,et al.  Anticarcinogenic activities of sulforaphane and structurally related synthetic norbornyl isothiocyanates. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[29]  W. Grizzle,et al.  Polyethylene Glycosylated Curcumin Conjugate Inhibits Pancreatic Cancer Cell Growth through Inactivation of Jab1 , 2009, Molecular Pharmacology.

[30]  Donald J L Jones,et al.  Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. , 2005, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[31]  B. Aggarwal,et al.  Nuclear factor‐κB and IκB kinase are constitutively active in human pancreatic cells, and their down‐regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis , 2004, Cancer.

[32]  P. Rothwell,et al.  Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials , 2012, The Lancet.

[33]  C. Rao,et al.  Chemoprevention of colonic aberrant crypt foci in Fischer rats by sulforaphane and phenethyl isothiocyanate. , 2000, Carcinogenesis.